Tag - OCGN


Cantor starts Ocugen at OW; PT $4.50

Cantor Fitzgerald launched coverage of Ocugen (NASDAQ:OCGN) with an “overweight” rating and price target of $4.50. The stock closed at $2.17 on June 1. Ocugen is a clinical-stage biotechnology company focused on...


HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...


Ocugen to discontinue Phase 3 oGVHD trial

Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...